Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...
On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose ...
Subject to shareholder approval at the subsequent Annual General Meeting (AGM), the Board of Directors of Sanofi Consumer ...
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...
Health2Sync Deepens Reach and Partnerships in South Korea with Growing Adoption of its Digital Disease Management Platform ...
Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback